Lipocine Inc. reported that the last patient completed the final study visit (last patient last visit) in its pivotal Phase 3 randomized, double-blind, placebo-controlled trial of LPCN 1154 (oral brexanolone) for postpartum depression. The study enrolled 90 patients with severe postpartum depression and is evaluating change from baseline in Hamilton depression rating scale (HAM-D) score at Hour 60 as the primary endpoint. Lipocine said safety observations to date included mild-to-moderate nervous system adverse events, with no discontinuations, excessive sedation, loss of consciousness, or drug-related serious adverse events reported. Efficacy results were not presented in the announcement and are expected to be reported in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lipocine Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602180800PR_NEWS_USPR_____LA90193) on February 18, 2026, and is solely responsible for the information contained therein.